MACKNASDAQHealthcare · Biotechnology

Merrimack Pharmaceuticals, Inc.

$15.14+0.10%(+$0.01)

TickerSpark Score

65/100

Solid

Valuation

Profitability

Growth

Health

100

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MACK research report →

52-Week Range83% of range

Low $11.53

Current $15.14

High $15.89

Companywww.merrimack.com

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

CEO: Gary L. Crocker
IPO: 2012
HQ: Cambridge, MA, US

Price Chart

+21.04% · this period

Valuation

Market Cap: $223.97M
P/E: -183.37
P/S: 0.00
P/B: 11.55
EV/EBITDA: 216.47
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -6.22%
ROIC: -11.61%

Growth & Income

Revenue: $0 · 0.00%
Net Income: $-1,181,000 · 23.51%
EPS: $-0.08 · 24.91%
Op Income: $-2,176,000
FCF YoY: 12.63%

Performance & Tape

52W High: $15.89
52W Low: $11.53
50D MA: $14.80
200D MA: $13.36
Beta: 1.42
Avg Volume: 182.63K

Get TickerSpark's AI analysis on MACK

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

Date	Insider	Role	Type	Shares	Value
Dec 28, 23	Andersen Eric	director	buy	857	$11.44K
Dec 26, 23	Andersen Eric	director	buy	48,693	$640.31K
Dec 7, 23	Andersen Eric	director	buy	76,384	$981.52K
Dec 7, 23	Andersen Eric	director	buy	24,666	$316.95K
Nov 17, 23	Andersen Eric	director	buy	235	$2.94K
Nov 17, 23	Andersen Eric	director	buy	65	$812.5
Nov 14, 23	Andersen Eric	director	buy	39,283	$491.04K
Nov 14, 23	Andersen Eric	director	buy	10,887	$136.09K
Nov 9, 23	Andersen Eric	director	buy	7,810	$95.22K
Nov 8, 23	Andersen Eric	director	buy	4,783	$58.03K